期刊
NATURE REVIEWS CANCER
卷 8, 期 12, 页码 929-941出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc2459
关键词
-
类别
资金
- Cancer Research UK
- Medical Research Council, UK
- British Heart Foundation
- European Union Framework Programme 6 [LSH-2002-2]
- Biotechnology and Biological Sciences Research Council, UK
Over the last few years disintegrin metalloproteinases of the Adam (a disintegrin and metalloproteinase) family have been associated with the process of proteolytic 'shedding' of membrane-associated proteins and hence the rapid modulation of key cell signalling pathways in the tumour microenvironment. Furthermore, numerous members of the Adam family have been associated with tumorigenesis and tumour progression. The question now arises of whether pharmacological manipulation of their functions would be a useful adjunct to therapies targeting intercellular communications. To learn from the lessons of matrix metalloproteinase inhibitors as anticancer agents, there are many facets of the biological and clinical relevance of the ADAMs that need to be understood before embarking with confidence on such an approach.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据